Molnupiravir—A Novel Oral Anti-SARS-CoV-2 Agent
Since December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly resulted in a global pandemic with approximately 4 million deaths. Effective oral antiviral agents are urgently needed to treat coronavirus disease-2019 (COVID-19), block SARS-CoV-2 transmission, and preven...
Guardado en:
Autores principales: | Ching-Chi Lee, Chih-Chia Hsieh, Wen-Chien Ko |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/74981b2833ae44b6bb4f9ec78331bb5d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Molnupiravir; an effective drug in treating COVID-19?
por: Alireza Pouramini, et al.
Publicado: (2022) -
Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease
por: Maria L. Agostini, et al.
Publicado: (2018) -
Antiviral research
Publicado: (1981) -
A Novel Intronic Circular RNA Antagonizes Influenza Virus by Absorbing a microRNA That Degrades CREBBP and Accelerating IFN-β Production
por: Zhiyuan Qu, et al.
Publicado: (2021) -
Identification of the I38T PA Substitution as a Resistance Marker for Next-Generation Influenza Virus Endonuclease Inhibitors
por: Jeremy C. Jones, et al.
Publicado: (2018)